Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
ACRV
Acrivon Therapeutics, Inc.
NASDAQGM
Biotechnology
United States
$2.13
▲
+0.07 (+3.40%)
CLOSED
—
OPEN
$2.06
HIGH
$2.14
LOW
$2.06
PREV CLOSE
$2.06
VOLUME
184.5K
0.48x avg
BID / ASK
1.14 / 2.06
spr 0.920
MARKET CAP
$91.3M
DAY RANGE
$2.06
$2.14
P/E (TTM)
—
Fwd -1.3
EPS (TTM)
-1.95
DIV YIELD
—
52W HIGH
$3.56
-40.2%
52W LOW
$1.27
+67.7%
BETA
1.93
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$2.18
+0.05
(+2.35%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
ACRV
$2.13
▲
+3.40%
Chart
Valuation
Financials
Peers
News
ACRV · K 線技術分析（即時、可互動）
basic
pro
快速分析（約半分鐘，最長 5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，通常約半分鐘，上游壅塞時最長 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-ON
252 BARS · +60.2% YOY
1-year price chart. Started at 1.33, currently 2.13, up 60.2 percent. Range 1.29 to 3.01 over 252 data points.
2025-09-05
$1.33 → $2.13 (+60.2%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers. · Comparables skipped: no peer multiples or no per-share economics from Finnhub metric endpoint.
FINANCIALS
多年財務（SEC XBRL）
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$77.9M
-$63.7M
-$65.3M
$129.7M
2024-12
—
-$80.6M
-$65.7M
-$68.4M
$196.6M
2023-12
—
-$60.4M
-$42.6M
-$43.9M
$138.3M
NEWS
近期新聞（過去 14 天）
—
7 HEADLINES · LAST 14 DAYS
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
Zacks · 2026-09-03
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
GlobeNewswire · 2026-09-02
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
GlobeNewswire · 2026-08-31
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Zacks · 2026-08-24
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
GlobeNewswire · 2026-08-12
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
GlobeNewswire · 2026-08-05
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
GlobeNewswire · 2026-07-21